<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cholecalciferol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00169</strong>&#160; (APRD00506, NUTR00008)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, nutraceutical</td></tr><tr><th>Description</th><td><p>Derivative of 7-dehydroxycholesterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from ergocalciferol in having a single bond between C22 and C23 and lacking a methyl group at C24. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00169/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00169/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00169.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00169.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00169.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00169.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00169.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00169">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(+)-vitamin D3</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>calciol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>CC</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Colecalciferol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vitamin D3</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Micro-D</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Optimal-D</td><td>RV Nutritional, LLC</td></tr><tr><td>Vigantol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Spectrum</td><td>Beta-Carotene (Provitamin a) + Biotin + Calcium + Copper + D-Pantothenic Acid + Folic Acid + Iodine + Iron + Magnesium + Nicotinamide + Phosphorus + Vitamin a (Vitamin a Acetate) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate)</td></tr><tr><td>Spectrum Forte</td><td>Beta-Carotene (Provitamin a) + Biotin + Calcium + Chlorine (Potassium Chloride) + Chromium + Copper + D-Pantothenic Acid + Folic Acid + Iodine + Iron + Magnesium + Manganese + Molybdenum (Sodium Molybdate) + Nickel + Nicotinamide + Phosphorus + Potassium + Selenium + Silicon + Tin (Stannous Chloride) + Vanadium + Vitamin a (Vitamin a Acetate) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate) + Zinc</td></tr><tr><td>Spectrum Gold</td><td>Beta-Carotene (Provitamin a) + Biotin + Calcium + Chlorine (Potassium Chloride) + Chromium + Copper + D-Pantothenic Acid + Folic Acid + Iodine + Iron + Magnesium + Manganese + Molybdenum (Sodium Molybdate) + Nickel + Nicotinamide + Phosphorus + Potassium + Selenium + Silicon + Tin (Stannous Chloride) + Vanadium + Vitamin a (Vitamin a Acetate) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate) + Zinc</td></tr><tr><td>Watkin's Super Multi</td><td>Beta-Carotene (Provitamin a) + Biotin + Calcium (Calcium Phosphate (Dibasic), Calcium Citrate) + Chromium + Copper (Copper Gluconate) + D-Pantothenic Acid + Folic Acid + Magnesium + Manganese + Molybdenum (Sodium Molybdate) + Nicotinic Acid + Phosphorus + Selenium (Selenium Hvp Chelate) + Vanadium (Vanadium Hvp Chelate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 + Vitamin B2 (Riboflavin, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin D (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate) + Zinc</td></tr><tr><td>Watkins J.R.</td><td>Beta-Carotene (Provitamin a) + Biotin + Chromium + Copper (Copper Sulfate) + D-Pantothenic Acid + Folic Acid + Iodine + Iron + Manganese + Molybdenum (Sodium Molybdate) + Nicotinamide + Selenium (Selenium Hvp Chelate) + Silicon (Silicon Dioxide) + Vitamin B1 (Thiamine Mononitrate) + Vitamin B12 (Cyanocobalamin) + Vitamin B2 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin D (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate, D-Alpha Tocopheryl Acid Succinate) + Zinc (Zinc Hvp Chelate, Zinc Citrate)</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/bone-density-conservation-agents">Bone Density Conservation Agents</a></li>
<li><a href="/mesh/vitamins">Vitamins</a></li>
<li><a href="/mesh/antithyroid-agents">Antithyroid Agents</a></li>
<li><a href="/mesh/vitamin-d">Vitamin D</a></li>
<li><a href="/mesh/antihypocalcemic-agents">Antihypocalcemic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>67-97-0</td></tr><tr><th>Weight</th><td>Average: 384.6377<br>Monoisotopic: 384.33921603</td></tr><tr><th>Chemical Formula</th><td>C<sub>27</sub>H<sub>44</sub>O</td></tr><tr><th>InChI Key</th><td>QYSXJUFSXHHAJI-YRZJJWOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00169.gif?1265922773">show</a>(11.1 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Vitamin D and Derivatives</td></tr><tr><th>Direct parent</th><td>Vitamin D and Derivatives</td></tr><tr><th>Alternative parents</th><td>Sesterterpenes; Cyclohexanols; Cyclic Alcohols and Derivatives; Polyamines</td></tr><tr><th>Substituents</th><td>cyclohexanol; cyclic alcohol; secondary alcohol; polyamine; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.</td></tr><tr><th>Pharmacodynamics</th><td>Cholecalciferol (vitamin D3) is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of Vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.</td></tr><tr><th>Mechanism of action</th><td>The first step involved in the activation of vitamin D3 is a 25-hydroxylation which is catalysed by the 25-hydroxylase in the liver and then by other enzymes. The mitochondrial sterol 27-hydroxylase catalyses the first reaction in the oxidation of the side chain of sterol intermediates. The active form of vitamin D3 (calcitriol) binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.</td></tr><tr><th>Absorption</th><td>Readily absorbed</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>50% to 80%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Within the liver, cholecalciferal is hydroxylated to calcidiol (25-hydroxycholecalciferol) by the enzyme 25-hydroxylase. Within the kidney, calcidiol serves as a substrate for 1-alpha-hydroxylase, yielding calcitriol (1,25-dihydroxycholecalciferol), the biologically active form of vitamin D3.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Cholecalciferol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00609">(23S)-23,25-dihdroxy-24-oxovitamine D3 23-(beta-glucuronide)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/627">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Several weeks</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Hypercalcemia - Early symptoms of hypercalcemia, include nausea and vomiting, weakness, headache, somnolence, dry mouth, constipation, metallic taste, muscle pain and bone pain. Late symptoms and signs of hypercalcemia, include polyuria, polydipsia, anorexia, weight loss, nocturia, conjunctivitis, pancreatitis, photophobia, rhinorrhea, pruritis, hyperthermia, decreased libido, elevated BUN, albuminuria, hypercholesterolemia, elevated ALT (SGPT) and AST (SGOT), ectopic calcification, nephrocalcinosis, hypertension and cardiac arrhythmias.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Lysosomal Acid Lipase Deficiency (Wolman Disease)</td><td>Disease</td></tr><tr><td>Mevalonic aciduria</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00510?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00510</a></td></tr><tr><td>Pravastatin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00089?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00089</a></td></tr><tr><td>Rosuvastatin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00092?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00092</a></td></tr><tr><td>Alendronate Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00095?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00095</a></td></tr><tr><td>Ibandronate Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00079?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00079</a></td></tr><tr><td>Simvastatin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00082?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00082</a></td></tr><tr><td>Lovastatin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00099?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00099</a></td></tr><tr><td>Zoledronate Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00107?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00107</a></td></tr><tr><td>Cerivastatin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00111?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00111</a></td></tr><tr><td>Risedronate Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00112?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00112</a></td></tr><tr><td>Pamidronate Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00117?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00117</a></td></tr><tr><td>Fluvastatin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00119?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00119</a></td></tr><tr><td>Atorvastatin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00131?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00131</a></td></tr><tr><td>Steroid Biosynthesis</td><td>Metabolic</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00023?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00023</a></td></tr><tr><td>Chondrodysplasia Punctata II, X Linked Dominant (CDPX2)</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00388?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00388</a></td></tr><tr><td>CHILD Syndrome</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00387?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00387</a></td></tr><tr><td>Cholesteryl ester storage disease</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00508?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00508</a></td></tr><tr><td>Desmosterolosis</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00386?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00386</a></td></tr><tr><td>Wolman disease</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00511?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00511</a></td></tr><tr><td>Hyper-IgD syndrome</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00509?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00509</a></td></tr><tr><td>Hypercholesterolemia</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00209?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00209</a></td></tr><tr><td>Smith-Lemli-Opitz Syndrome (SLOS)</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00389?highlight%5Bcompounds%5D%5B%5D=DB00169&amp;highlight%5Bproteins%5D%5B%5D=DB00169">SMP00389</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.959</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8342</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6706</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7603</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5346</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7818</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8384</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7302</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9256</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9551</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7881</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7093</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.921
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9878
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.9310 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.773
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7589
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.chaindrug.com">Chain Drug</a></li>
<li><a href="http://www.cvs.com">CVS Pharmacy</a></li>
<li><a href="http://www.freedavitamins.com">Freeda Vitamins</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li>Mason Distributors</li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li>MSD Frosst Iberica SA</li>
<li><a href="http://www.pharmavite.com">Pharmavite</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Professional Co.</li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01436">Alfacalcidol</a></td><td>Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. </td></tr><tr><td><a href="/drugs/DB06723">Aluminum hydroxide</a></td><td>Vitamin D analogs such as cholecalciferol may increase the serum concentration of aluminum hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. </td></tr><tr><td><a href="/drugs/DB02300">Calcipotriol</a></td><td>Vitamin D Analogs may enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). hough not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. </td></tr><tr><td><a href="/drugs/DB00136">Calcitriol</a></td><td>Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. </td></tr><tr><td><a href="/drugs/DB01432">Cholestyramine</a></td><td>Bile acid sequestrants such as cholestyramine may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. </td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. </td></tr><tr><td><a href="/drugs/DB00375">Colestipol</a></td><td>Bile acid sequestrants such as colestipol may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. </td></tr><tr><td><a href="/drugs/DB06410">Doxercalciferol</a></td><td>Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. </td></tr><tr><td><a href="/drugs/DB00153">Ergocalciferol</a></td><td>Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. </td></tr><tr><td><a href="/drugs/DB01083">Orlistat</a></td><td>Orlistat may decrease the serum concentration of Vitamin D analogs. More specifically, orlistat may impair absorption of Vitamin D analogs such as cholecalciferol. Monitor clinical response (plasma calcium concentrations) to orally administered vitamin D analogs closely if used with orlistat. When this combination must be used, consider administering the vitamin D analog at least 2 hours before or after the administration of orlistat. </td></tr><tr><td><a href="/drugs/DB00910">Paricalcitol</a></td><td>Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. </td></tr><tr><td><a href="/drugs/DB00364">Sucralfate</a></td><td>Vitamin D analogs such as cholecalciferol may increase the serum concentration of sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>